908 Devices (MASS) Stifel 2025 Healthcare Conference summary

Business transformation and portfolio expansion

• Completed acquisition of RedWave and divested PAT business, expanding handheld product portfolio from one to five products and strengthening the balance sheet with $70 million in proceeds, ending the quarter with $112 million in cash.

• Consolidated manufacturing to Danbury, CT, reducing costs and supporting the goal of achieving adjusted positive EBITDA in Q4.

• Focused on drug detection, security, and toxic material identification, leveraging secular tailwinds in handheld device demand.

• Leveraged existing sales force for RedWave integration, enabling efficient scaling and international expansion.

Revenue performance, guidance, and diversification

• Reported $14 million in Q3 revenue, exceeding consensus, and reiterated full-year guidance of $54–$56 million.

• Approximately 47% of year-to-date revenue comes from state and local channels, with 25% from international, reducing reliance on federal contracts.

• Federal government shutdown delayed $4 million in Q4 revenue, with $3 million tied to federal/military and $1–$3 million in international orders awaiting export licenses.

• State and local sales driven by urgent needs for fentanyl and industrial chemical detection, supported by multi-year federal grants.

Key growth drivers and product innovation

• Major growth catalysts include the launch of VipIR and XplorIR, with VipIR targeting customs, hazmat, and law enforcement, and XplorIR capable of identifying 5,000 gases.

• Next-generation MX908 handheld mass spectrometer expected to launch in late 2025/2026, offering smaller, lighter, and easier-to-use features.

• Over 3,000 MX908 units deployed, with upgrade opportunities as new products launch.

• VipIR currently has lower gross margins due to early-stage production but is expected to improve as volumes scale.